secwatch.observer — SEC 8-K summary
======================================

Issuer:     NewAmsterdam Pharma Co N.V. (NAMS)
CIK:        0001936258
Form:       8-K
Filed at:   2024-07-29T23:59:59+00:00
Accession:  0001193125-24-186747
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NAMS: Phase 3 BROOKLYN trial of obicetrapib meets primary endpoint; LDL-C down 36.3% at day 84
--------------------------------------------------------------------------------

- LDL-C reduced 36.3% vs placebo at day 84 and 41.5% at day 365, both p<0.0001.
- 51% of patients on obicetrapib achieved LDL-C below 70 mg/dL.
- Safety comparable to placebo; TEAEs 63.7% vs 70.3%, discontinuation 7.6% vs 14.4%.
- Mean baseline LDL-C was 123 mg/dL despite 79% on high-intensity statins.
- Next data readouts: BROADWAY (Q4 2024) and TANDEM (Q1 2025).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/0001193125-24-186747-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1936258/000119312524186747/d660026d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-186747

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer